회사 개요
UnitedHealth Group Incorporated operates as a comprehensive healthcare entity serving both domestic and international markets through four distinct segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which collectively provide care delivery, care management, wellness services, and consumer engagement solutions. The company functions within the broader Healthcare sector, specifically categorized under the Healthcare Plans industry, positioning it as a major player in the administration and financing of medical services alongside direct care provision. Its substantial scale is evidenced by a market capitalization of $277.73B, annual revenue of $447.57B, and a workforce comprising 390,000 employees, establishing it as one of the largest publicly traded entities in the United States. These valuation and revenue figures indicate a dominant market position that allows the firm to leverage its extensive infrastructure to influence industry standards and secure a significant foothold in the global health economy.
재무 건전성
The financial performance metrics for UnitedHealth Group show a trailing twelve-month revenue of $447.57B, with a net income of $12.06B and an EBITDA of $21.62B, revealing a significant gap between top-line revenue and bottom-line profit that highlights a substantial cost structure involving administrative overhead, medical expense reimbursements, and operational expenditures. The company generates $13.86B in free cash flow, which signifies robust financial flexibility enabling capital allocation for strategic acquisitions, debt reduction, or share repurchases without relying solely on external financing. Marginal analysis indicates a gross margin of 18.5%, reflecting the inherent cost pressures of the healthcare services sector, an operating margin of 0.3% which underscores the intense competition and high fixed costs in managing healthcare plans, and a profit margin of 2.7% that demonstrates the company's ability to convert revenue into earnings despite operational complexities. On the balance sheet, the firm holds $28.12B in cash against $83.00B in total debt, resulting in a debt-to-equity ratio of 81.62, which suggests a leveraged capital structure where interest obligations are substantial relative to equity capitalization. Liquidity assessment via the current ratio of 0.79 indicates that current assets fall short of current liabilities, suggesting a reliance on operating cash flows or refinancing to meet short-term obligations rather than holding excess liquid assets. Return on equity stands at 12.5% while return on assets is 3.9%, metrics that reveal management's effectiveness in generating shareholder value relative to equity invested and utilizing the total asset base to produce net income, respectively.
밸류에이션 평가
Valuation multiples for UnitedHealth Group indicate a trailing P/E ratio of 23.15 compared to a forward P/E of 15.22, implying that the market expects a significant contraction in earnings or a re-rating of valuation standards if the forward projection is to be met, as the substantial difference between the two ratios often signals anticipated challenges in future profitability. The price-to-book ratio is recorded at 2.95, indicating that the stock trades at nearly three times its book value, which suggests the market assigns a premium to the company's intangible assets, brand strength, and future growth potential beyond the tangible net asset value. Alternative valuation metrics include a price-to-sales ratio of 0.62 and an EV/EBITDA of 15.73, figures that suggest the company is valued at a discount relative to its sales base but commands a premium over its earnings power when adjusted for enterprise value and debt. Technical price data shows a 52-week high of $606.36 and a 52-week low of $234.60, establishing a wide trading range that reflects significant price volatility and potential for substantial capital appreciation or correction depending on market sentiment. The beta coefficient of 0.41 indicates that the stock price exhibits low volatility relative to the broader market, moving less than half as much as the market index, which offers a lower-risk profile for investors seeking stability within the healthcare sector.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 12.3% year-over-year contrasted with an earnings growth rate of -99.9% year-over-year, a divergence that implies a severe decline in profitability or one-time charges impacting net income far more than revenue expansion. As a consistent dividend payer, the company distributes a dividend yield of 2.9% with a payout ratio of 66.0%, a level that requires careful scrutiny given the recent negative earnings growth, as maintaining such a payout without positive earnings growth may necessitate drawing down cash reserves or increasing debt. The substantial drop in earnings growth relative to revenue highlights the fragility of current profitability metrics, suggesting that the earnings figure may be under significant pressure from operational costs, regulatory changes, or specific segment underperformance. Overall, the company presents a profile of strong top-line expansion supported by a high dividend yield, yet the negative earnings growth and leveraged balance sheet introduce complexity into the investment thesis regarding future income sustainability.